Back HIV/AIDS

HIV / AIDS

CROI 2014: Monkey Studies Confirm Validity of Injectable PrEP

Two studies in monkeys of an injectable formulation of the third-generation integrase inhibitor drug GSK1265744 (or GSK744LA, where LA stands for "long-acting") have strengthened the evidence that it may work as pre-exposure prophylaxis (PrEP) in humans, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. A Phase 2 study in humans will be starting soon.

alt

CROI 2014: Depression and HIV are Risk Factors for Heart Failure Among Veterans

Both HIV infection and depression are independent risk factors for incident heart failure, and living with both HIV and depression multiplies the risk, according to an analysis of data from the Veterans Aging Cohort Study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Raltegravir Plus Boosted Darunavir Is Safe and Effective for First-line ART

A NRTI-sparing initial regimen of raltegravir (Isentress) plus boosted darunavir (Prezista) worked as well as traditional antiretroviral therapy containing tenofovir/emtricitabine (the drugs in Truvada), according to findings from the NEAT 001 study reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Tesamorelin Growth-Hormone Releaser Reduces Liver Fat in People with HIV

Tesamorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), which the FDA has approved to reduce excess visceral abdominal fat in people living with HIV, also reduced associated liver fat in an HIV positive cohort chosen for abdominal adiposity, according to the results from a randomized, placebo-controlled trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: HIV Transmission through Condomless Sex [VIDEO]

An analysis of more than 750 serodiscordant heterosexual and gay couples in the PARTER study who engaged in more than 45,000 condomless sex acts found no cases of linked HIV transmission when the positive partner was on effective antiretroviral therapy (ART), confirming that treatment as prevention works, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Men Not Benefiting as Much as Women from HIV Treatment in Africa [VIDEO]

Scale-up of antiretroviral therapy (ART) has led to a much larger reduction in mortality for women than for men, according to a report presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: HIV Treatment as Prevention Works in PARTNER Study

No cases of linked HIV transmission were seen during 44,500 condomless sex acts by more than 750 heterosexual and gay couples, according to findings from the PARTNER study presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2014).

Treatment as Prevention Dramatically Lowers HIV Sexual Transmission [Press conference video]

No One with Undetectable Viral Load Transmits HIV in PARTNER Study [Study summary]

HIV Transmission through Condomless Sex [Interview with Jens Lundgren]

3/5/14

alt